Targovax (NO: TRVX)

Last close As at 27/03/2024

9.07

0.00 (0.00%)

Market capitalisation

785m

Edison Investment Research is terminating coverage on Targovax. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

View More

Healthcare | Update

Targovax — Confirmatory 12-month mesothelioma update

Healthcare | Update

Targovax — ONCOS-102 plus durvalumab trial in spotlight

Healthcare | Update

Targovax — More data in 2020 from both clinical trials

Financials

Edison Investment Research is terminating coverage on Targovax. Please note you should no longer rely on any previous research or estimates for these companies. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Thematics

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

thematic

Healthcare

ASCO 2023 key takeaways

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free